Change in Sub-aspects of Vision-Related Quality of Life after Three Months of Using an App to Categorize Metamorphopsia

Abstract

Aim Distorted vision (metamorphopsia) is a leading symptom in retinal disease and can be categorized with the app MacuFix. This prospective controlled pilot study examined the influence of the app MacuFix as a method to assess metamorphopsia on vision-related quality of life.

Methods Forty-five patients suffering from metamorphopsia in at least one eye were recruited for the study. Vision-related quality of life before and after 3 months of optional home monitoring using the app MacuFix were compared with the questionnaire National Eye Institute Visual Function Questionnaire-25.

Results The 45 participants (18 women, 27 men) were, on average, 68 years old (SD ± 9.7) and had a mean best-corrected visual acuity of 0.6 (SD ± 0.25). Of 90 eyes, 18 revealed no maculopathy. Age-related macular degeneration existed in 52 eyes, epiretinal gliosis in 6, and macular hole in 1 eye. Macular edema was present in two eyes due to diabetes, four eyes due to uveitis, one eye after retinal venous thrombosis, four eyes because of an Irvine Gass syndrome, and two eyes caused by central serous thrombosis. After 3 months, 35 persons used the app for home monitoring, 8 persons applied the Amsler Grid, and 2 did not use any test. App users showed a highly significant improvement in vision-related quality of life in questions on mental health and concern about vision, and a significant improvement in performance, dejection, control, and embarrassing situations.

Conclusion The results suggest that MacuFix can possibly ameliorate partial aspects of vision-related quality of life.

Key words

metamorphopsia - vision-related quality of life - age-related macular degeneration - smartphone-based app

• References/Literatur

• 1 Wong WL, Su X, Li X. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2: e106-e116
• 2 Holz FG, Tadayoni R, Beatty S. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015; 99: 220-226
• 3 Wong TY, Lanzetta P, Bandello F. et al. Current concepts and modalities for monitoring the fellow eye in neovascular age-related macular degeneration: an expert panel consensus. Retina 2020; 40: 599-611
• 4 Colijn JM, Buitendijk GHS, Prokofyeva E. et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology 2017; 124: 1753-1763
• 5 Chew EY, Clemons TE, Bressler SB. et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 2014; 121: 535-544
• 6 Claessens D, Schuster AK, Krüger RV. et al. Test-Retest-Reliability of Computer-Based Metamorphopsia Measurement in Macular Diseases. Klin Monbl Augenheilkd 2021; 238: 703-710
• 7 Claessens D, Schuster AK. Korrelation der quantitativen Metamorphopsiemessung und der zentralen Netzhautdicke bei diabetischem Makulaödem und altersassoziierter exsudativer Makuladegeneration. Klin Monbl Augenheilkd 2019; 236: 877-884
• 8 Ugarte M, Shunmugam M, Laidlaw DA. et al. Morphision: a method for subjective evaluation of metamorphopsia in patients with unilateral macular pathology (i.e., full thickness macular hole and epiretinal membrane). Indian J Ophthalmol 2013; 61: 653-658
• 9 Matsumoto C, Arimura E, Okuyama S. et al. Quantification of metamorphopsia in patients with epiretinal membranes. Invest Ophthalmol Vis Sci 2003; 44: 4012-4016
• 10 Klatt C, Bunse A, Roider J. Erste klinische Erfahrungen mit PreView PHP (Zeiss) zur Quantifizierung von Metamorphopsien bei Erkrankungen der Makula. Klin Monbl Augenheilkd 2004; 221: V49
• 11 Schmid MK, Thiel MA, Lienhard K. et al. Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration. Eye (Lond) 2019; 33: 1584-1589
• 12 Mangione CM, Lee PP, Gutierrez PR. et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-1058
• 13 Claessens D, Krüger R. Interaktiver Test zur Kategorisierung eines verzerrten Seheindruckes. 32. Jahrestagung der Retinologischen Gesellschaft, 2019, Ludwigshafen.
• 14 Krüger R, Claessens D. Reliability of a Novel Computer-Based Metamorphopsia Categorization Tool. Invest Ophthalmol Vis Sci 2020; 61: 5067
• 15 Claessens D, Ichhpujani P, Singh RB. MacuFix^® versus Amsler grid for metamorphopsia categorization for macular diseases. Int Ophthalmol 2022; 42: 229-238
• 16 European Medicines Agency (EMEA), Committee for Proprietary Medical Products (CPMP). Points to consider on missing data. London; 2001. Im Internet (Stand: 15.11.2001): https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-missing-data_en.pdf
• 17 Ziemssen F, Khoramnia R, Feltgen N. et al. [Ophthalmology 3.0: chances for better patient information]. Ophthalmologe 2021; 118: 860-861
• 18 Hanumunthadu D, Lescrauwaet B, Jaffe M. et al. Clinical Update on Metamorphopsia: Epidemiology, Diagnosis and Imaging. Curr Eye Res 2021; 46: 1777-1791
• 19 Parikh R, Avery RL, Saroj N. et al. Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab. JAMA Ophthalmol 2019; 137: 914-920
• 20 Kawaguchi A, Sharafeldin N, Sundaram A. et al. Tele-Ophthalmology for Age-Related Macular Degeneration and Diabetic Retinopathy Screening: A Systematic Review and Meta-Analysis. Telemed J E Health 2018; 24: 301-308
• 21 Crossland M, Rubin G. The Amsler chart: absence of evidence is not evidence of absence. Br J Ophthalmol 2009; 91: 391-393
• 22 Carrasco J, Pietsch GA, Nicolas MP. et al. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. Adv Ther 2020; 37: 300-315
• 23 Ziemssen F, Feltgen N, Holz FG. et al. Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmol 2017; 17: 7
• 24 Liakopoulos S, Spital G, Brinkmann CK. et al. ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD). Br J Ophthalmol 2020; 104: 1573-1578
• 25 Muller S, Ehlken C, Bauer-Steinhusen U. et al. Treatment of age-related neovascular macular degeneration: the patientʼs perspective. Graefes Arch Clin Exp Ophthalmol 2017; 255: 2237-2246
• 26 Ulbig M, Höh H, Schmickler S. et al. Treatment reality with ranibizumab in clinical routine use for patients with diabetic macular edema: 1-year results of the German POLARIS cohort. Ophthalmologe 2019; 116: 631-639
• 27 Angermann R, Rauchegger T, Nowosielski Y. Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol 2019; 257: 2119-2125
• 28 Heier JS, Brown DM, Chong V. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548